✦ LIBER ✦

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

✍ Scribed by Adriana Martin, Robert Schellenberg

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of Hizentra® in pati

✍ S. Jolles; E. Bernatowska; J. de Gracia; M. Borte; V. Cristea; H.H. Peter; B.H. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 506 KB

Efficacy and Safety of IgPro20, a 20% Im

✍ Stephen Jolles; Victor Cristea; Volker Wahn; Marianne Debré; Hilary Longhurst; O 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Efficacy and Safety of Hizentra®, a New

✍ Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grim 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 182 KB

Efficacy and Safety of IgPro20, a Subcut

✍ Kanegane, Hirokazu; Imai, Kohsuke; Yamada, Masafumi; Takada, Hidetoshi; Ariga, T 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 212 KB

Efficacy and Safety of a New 20% Immunog

✍ John B. Hagan; Mary B. Fasano; Sheldon Spector; Richard L. Wasserman; Isaac Mela 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 197 KB

Efficacy and Safety of a New 20% Immunog

✍ Hagan, J.; Fasano, M.B.; Spector, S.; Wasserman, R.L.; Melamed, I.; Rojavin, M.A 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB